Postoperative adjuvant PD-1 immunotherapy survival and body-mass-index dynamics in esophageal cancer: A real-world retrospective study

Table 3 Adverse reactions during immunotherapy, n (%)

AE	Total (n = 44), AE (n = 12, 27.3%)
	Grade 1	Grade 2	Grade 3	Grade 4
Tiredness	3 (6.82)	1 (2.27)	/	/
Nausea	/	2 (4.55)	/	/
Hyperpigmentation	/	1 (2.27)	/	/
Fever	/	1 (2.27)	/	/
Hypothyroidism	/	1 (2.27)	/	/
Neutropenia	/	1 (2.27)	/	2 (4.55)

AE: Adverse event.